Compare Quest Diagnostics Inc (DGX) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Simon Property Group Inc — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while Simon Property Group Inc trades at $220.37 (market cap $71.76B). The key difference: Simon Property Group Inc is far larger — about 3.1× Quest Diagnostics Inc's market cap, and Simon Property Group Inc pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| DGX | SPG | |
|---|---|---|
Market Cap | $22.80B | $71.76B |
Sector | Health | Real Estate |
52-Week High | $216.02 | $227.56 |
52-Week Low | $166.42 | $159.93 |
Enterprise Value | $28.82B | $100.24B |
Dividend Yield | 1.67% | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SPG trades at $219.49, up 0.33% on the day, with a bearish technical signal despite bullish moving averages. The stock shows strong fundamentals with a 72.7% net income margin in 2025 and consistent earnings beats. Recent news highlights robust Q1 2026 results and a 4% dividend yield, though some analysts express caution on valuation. Cash flow trends indicate increased capital expenditures, with net cash flow turning negative in 2025.
Outlook remains mixed: strong leasing activity and raised FFO guidance support upside, but high debt levels and e-commerce risks weigh on sentiment. Analysts are predominantly neutral with a $214.40 consensus target, slightly below current price. Investors should balance income appeal against valuation concerns and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
